LOS ANGELES, Nov. 27, 2017 /PRNewswire/ -- CytRx Corporation
(NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, today announced that Chairman and
CEO, Steven A. Kriegsman, will
present at the LD Micro 10th Annual Main Event
Conference on Thursday, December 7,
2017 at 11:00 a.m. PT at the
Luxe Sunset Boulevard Hotel in Los
Angeles, CA.
A live and archived webcast of the event will be available at
http://wsw.com/webcast/ldmicro13/cytr.
As part of the Company's previously stated efforts to increase
its institutional shareholder base, CytRx is also planning to
present at the following future investor conferences:
Biotech Showcase 2018
January
8-10, 2018 (exact date and time TBD)
Hilton San Francisco Union Square,
San Francisco, CA
BIO CEO & Investor
Conference 2018
February 12-13,
2018 (exact date and time TBD)
New York Marriott Marquis Hotel, New
York, NY
30th Annual ROTH Conference
March 11-13, 2018 (exact date and
time TBD)
The Ritz Carlton, Laguna Niguel,
CA
Presentation dates and times, along with any links to potential
webcasts, will be provided closer to the actual events.
About CytRx Corporation
CytRx Corporation is a
biopharmaceutical company specializing in research and clinical
development of novel anti-cancer drug candidates that employ linker
technologies to enhance the accumulation and release of drug at the
tumor. CytRx is also rapidly expanding its pipeline of ultra-high
potency oncology candidates at its laboratory facilities in
Freiburg, Germany, through its LADR™ (Linker Activated Drug
Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker technology
for the development of a new class of potential breakthrough
anti-cancer therapies. Aldoxorubicin, CytRx's most advanced
drug conjugate, is an improved version of the widely used
chemotherapeutic agent doxorubicin and has been out-licensed to
NantCell, Inc.
Forward-Looking Statements
This press release
contains forward-looking statements. Such statements involve risks
and uncertainties that could cause actual events or results to
differ materially from the events or results described in the
forward-looking statements, including risks and uncertainties
relating to plans for regaining compliance with the Nasdaq rules
and higher share price of our common stock; the ability of
NantCell, Inc., to obtain regulatory approval for its products that
use aldoxorubicin; the ability of NantCell, Inc., to manufacture
and commercialize products or therapies that use aldoxorubicin; the
amount, if any, of future milestone and royalty payments that we
may receive from NantCell, Inc.; our ability to develop new
ultra-high potency drug candidates based on our
LADRTM technology platform; and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and Exchange Commission
and current reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-to-present-at-upcoming-investor-conferences-300561688.html
SOURCE CytRx Corporation